Study of 17 OHPC to Improve Outcomes in Women With Severe Preeclampsia Before 34 Weeks

What this Trial Is About

Researchers are evaluating whether giving 17-hydroxyprogesterone caproate 17 OHPC to mothers diagnosed with preeclampsia before 34 weeks of pregnancy improves outcomes for both mother and baby. This Phase 2 study focuses on severe or superimposed preeclampsia occurring preterm and aims to enhance the success of expectant management in these cases. Participants who join the study will receive 17 OHPC as an injection of 250mg into the muscle at admission and then weekly until delivery. Blood samples will be collected at baseline before the first injection, 24 hours later, every 72 hours thereafter until delivery, and once more 24 hours after delivery. Researchers will also collect placentas at birth and gather information about the mother and newborn during the hospital stay, including routine ultrasounds. During the study, participants will undergo regular blood tests and monitoring to assess maternal and perinatal health. Outcomes such as improvement in maternal and baby health will be measured, including changes within 24 hours after treatment. The study will continue to follow participants until hospital discharge, tracking clinical and molecular markers to evaluate the treatments impact over time.

Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia